TrialThe Journal of clinical endocrinology and metabolism2023

Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.

Kimball A Johnson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.